Member Info for Bermudashorts

Botski,

Not a clue, but if there is an opportunity to ask questions during the Proactive webinar on Thursday then that would be a good one.

Changes were made to the exclusion criteria section of the SCIB1 record on the clinical trials register yesterday. Previously any patients taking immune suppressants or systemic steroid therapy were excluded from the trial, with a couple of exceptions (ashtma/underactive thyroid). The trial protocol now allows for patients receiving steroids for adrenal insufficiency (Addison's) to be admitted to the trial, the following wording has been inserted:-

'The following patients are not excluded from the study: patients who receive physiological doses of steroids as replacement therapy, such as those for the management of adrenal insufficiency. In such cases the recruiting investigator should discuss the patients' eligibility with the study Medical Monitor prior to enrolment.'

Pure speculation but I wonder if this means that recruitment is up and running again and this change has arisen from screening.

https://clinicaltrials.gov/ct2/show/NCT04079166?term=scancell&draw=2&rank=1

Congratulations!

Ivy,

Bonkers isn't it? PDS is just one of NetScientific's portfolio companies. I think it's even one of their smaller holdings . Then factor in that today's press release is just headline data from PRECLINICAL testing with full details to be released later. On that news alone NSCI is over 100% up.

Scancell could release preclinical data at any time.

By the way, feel free to ask any questions you like, despite the bickering, there are some knowledgeable posters here both on Scancell and the science but also the wider pharma/bio sector too.

Alexios,

Interesting, thanks.

I don't believe he took the whole 18m.

Chelsea,

Actually I was grateful for Moljens support. You asked a question last night and I answered it as best I could. I felt GF123 misunderstood my answer.

As for the CLNs, they've hardly been discussed here. They're an important element of the total funding package and whilst they may not be converted, I think it's more realistic to assume they will. Most seem to assume that CLNs are bad news and certainly, I have been invested in bios where CLNs have been a disaster but equally, there have been others where they have provided a mutually beneficial and valuable source of funding. It all depends on the quality of the company, how it performs going forwards and how the CLNs are managed.

Redmile won't have accepted interest free CLNs out of the goodness of their heart, they will expect to see a return on the loan. However, despite scaremongering talk of death spiral funding, we need to remember that risk is mitigated by Redmile's long position in Scancell. They are holding just under 91m shares and have more incentive than any of us to see Scancell's share price rise.

Rather than assume they won't be converted, it might be useful to have an open discussion about them as I'm sure some readers here may have some unfounded concerns and some it might help.

I have a bit to say about Redmile (positive) and when I have time, will write up a post.

GF123

For clarity, I haven't expressed any opinion as to whether or not I think they'll be converted.

Ruck,

Current shares in issue 465,355,867
£2m placing 36,363,636
£5m subscription 90,909,090
Open Offer 36,498,499

Chelsea,

It's easily done when a funding has so many different elements.

As for the general situation, I'm thrilled that finally a specialist healthcare fund has invested in Scancell. As you know, the lack of investment from a biotech. fund has been a concern to me and that's now been put to bed.

GF123

I didn't say the answer was 725m and your 22.17 isn't an alternative view - it's exactly the same view as my original answer which was:-

'I make it 629m excluding any CLN shares. If/when the CLNs are converted that will add just under 97m bringing the total to 725m.'

Which is precisely why I used the word 'if'

I thought you were trying to work out the total number of shares in issue following this round of funding, hence my if/when qualification with the CLNs

Chelsea,

Correct, re. market cap. and CLNs

GF123 -

Sorry, not sure what point you're making.

Chelsea,

I make it 629m excluding any CLN shares. If/when the CLNs are converted that will add just under 97m bringing the total to 725m.

Courtesy of Botski on the Scancell board, Richard Barfield will be presenting at the Proactive One2One on 30th July - you can register for the webinar here:-

https://www.proactiveinvestors.co.uk/register/event_details/260

Botski,

Thanks for that. You can register via link below:-

https://www.proactiveinvestors.co.uk/events/

Have just been reading through the documentation issued yesterday, in particular around Covidity. This sentence stood out:-

'Scancell is actively seeking development partners and additional funding (including non-dilutive funding from governments and global institutions)'

The 'global institutions' part is interesting, we all know that Scancell have applied to UKRI for UK Government funding but they clearly have applied to other institutions. Global institutions would possibly include organisations like CEPI, philanthropic organisations such as Bill & Melinda Gates Foundation etc.

Guys,

Anyone looking through share chat or anyone who may be looking at SCLP for the first time is just seeing post after post with the title DILUTION.

Just saying.